{
    "UI_visible_response": "The heparin contamination crisis in 2008 was primarily linked to the raw heparin stock imported from mainland China. It was reported that the contaminant found was “likely made in China from animal cartilage, chemically altered to act like heparin”7. This contamination led to significant health issues, including about 350 adverse events and 150 deaths in the United States1. The crisis highlighted challenges in the supply chain and regulatory oversight, prompting increased FDA enforcement and policy changes regarding the import of drug substances9. While the contamination originated from suppliers in China, the responsibility also extended to the companies that sourced the heparin, such as Baxter, and the regulatory bodies tasked with ensuring the safety of pharmaceuticals6.",
    "traffic_visible_response": "The heparin contamination crisis in 2008 was primarily linked to the raw heparin stock imported from mainland China. It was reported that the contaminant found was “likely made in China from animal cartilage, chemically altered to act like heparin” [[7]]. This contamination led to significant health issues, including about 350 adverse events and 150 deaths in the United States [[1]]. The crisis highlighted challenges in the supply chain and regulatory oversight, prompting increased FDA enforcement and policy changes regarding the import of drug substances [[9]]. While the contamination originated from suppliers in China, the responsibility also extended to the companies that sourced the heparin, such as Baxter, and the regulatory bodies tasked with ensuring the safety of pharmaceuticals [[6]].",
    "block_type": "REG",
    "search_status": "search_completed",
    "indicators": "not_filtered"
}